277 results on '"Mackie, Sarah L"'
Search Results
2. Polymyalgia rheumatica shows metabolomic alterations that are further altered by glucocorticoid treatment: Identification of metabolic correlates of fatigue
3. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study
4. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
5. Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseases
6. Polymyalgia rheumatica
7. Test-retest reliability of pain VAS/NRS, stiffness VAS/NRS, HAQ-DI and mHAQ in polymyalgia rheumatica: An OMERACT study
8. A methodological framework for AI-assisted diagnosis of active aortitis using radiomic analysis of FDG PET–CT images: Initial analysis
9. Imaging of giant cell arteritis – recent advances
10. Estimating overdiagnosis in giant cell arteritis diagnostic pathways using genetic data: genetic association study.
11. Micro-RNA content of circulating extracellular vesicles in early rheumatoid arthritis as biomarkers and mediators of methotrexate efficacy.
12. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study
13. Genetically predicted serum urate levels have no causal role on depression or other psychiatric disorders
14. Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective
15. Practice points for ophthalmologists from the 2020 British Society for Rheumatology Giant Cell Arteritis guidelines
16. Validation of a new glucocorticoid-specific Patient-Reported Outcome Questionnaire (the Steroid PRO).
17. The Patientsʼ Perspective of Important Glucocorticoid Effects: A Nominal Group Study Among Patients With Systemic Lupus Erythematosus and Myositis
18. Life after tocilizumab given for giant cell arteritis: a patient survey and argument for re-treatment.
19. Characteristics of patients with giant cell arteritis who experience visual symptoms
20. Jaw claudication and jaw stiffness in giant cell arteritis: secondary analysis of a qualitative research dataset.
21. Treatment of polymyalgia rheumatica: British Society for Rheumatology guideline scope.
22. Does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?
23. Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment–specific patient-reported outcome measure.
24. Tocilizumab and glucocorticoids for giant cell arteritis: the learning curve
25. An Automated Method for Artifical Intelligence Assisted Diagnosis of Active Aortitis Using Radiomic Analysis of FDG PET-CT Images
26. Common co-morbidities in polymyalgia rheumatica and giant cell arteritis: cross-sectional study in UK Biobank.
27. Giant cell arteritis can occur in people of colour
28. A Survey of Glucocorticoid Adverse Effects and Benefits in Rheumatic Diseases: The Patient Perspective
29. Polymyalgia rheumatica
30. Angiotensin receptor blockade is associated with increased risk of giant cell arteritis.
31. Improving COVID-19 Vaccine Coverage in Patients With Autoimmune and Inflammatory Diseases: Dr. Conway et al reply
32. A shared basis for overlapping immunopathologies in giant cell arteritis and polymyalgia rheumatica
33. Scienced by blinding: ultrasound for giant cell arteritis
34. Response to: ‘A relationship between extracapsular involvement and response to steroid treatment in polymyalgia rheumatica: too soon to conclude?’ by Yang et al
35. Feasibility and face validity of outcome measures for use in future studies of Polymyalgia Rheumatica (PMR): An OMERACT Study
36. Variability in counselling for adrenal insufficiency in COVID-19 and beyond: a survey of rheumatology practice
37. HLA allele variation as a potential explanation for the geographical distribution of granulomatosis with polyangiitis
38. Developing consensus in Histopathology: the role of the Delphi method.
39. VASCULITIS SYNDROMES: Dealing with increased vascular risk and mortality in GCA
40. Genetically proxied IL-1 receptor antagonism and risk of polymyalgia rheumatica.
41. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis
42. Should race be considered in diagnosing giant cell arteritis? – Authors' reply
43. Game-changing therapies for people with giant cell arteritis?
44. Co-stimulatory blockade as therapy for rheumatoid arthritis
45. Relationship between area-level socio-economic deprivation and autoantibody status in patients with rheumatoid arthritis: multicentre cross-sectional study
46. Comment on: Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors: reply
47. Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors
48. Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study
49. RESULTS OF A PATIENT SURVEY ON FEASIBILITY AND FACE VALIDITY OF OUTCOME MEASURES FOR INTENDED USE IN FUTURE STUDIES ENROLLING PARTICIPANTS WITH POLYMYALGIA RHEUMATICA
50. Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.